Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Philippine lawyers sue...

    Philippine lawyers sue Sanofi over dengue vaccine

    Written by Ruby Khatun Khatun Published On 2018-02-09T09:30:20+05:30  |  Updated On 16 Aug 2021 4:05 PM IST

    MANILA: A Philippine government agency filed a lawsuit against French drugmaker Sanofi demanding compensation for the parents of a 10-year-old girl the agency said had died as a result of receiving its controversial anti-dengue vaccine.


    The Public Attorney's Office (PAO) said Sanofi, several former and current health ministry officials and domestic distributor Zuellig Pharma Corp must be declared jointly liable for the death of Anjielica Pestilos.


    Pestilos was one of the more than 800,000 Filipino children aged nine and above who had been inoculated with Dengvaxia.


    The agency is seeking compensation of up to 4.2 million pesos ($81,600) over her death. PAO said Pestilos should not have been given the vaccine because a forensic examination showed she had a pre-existing disease.



    "So much bleeding from her lungs, her liver, her heart, her stomach were from viscerotropic-like disease which was caused by the injection of Dengvaxia," PAO forensic expert Erwin Erfe told a news conference, explaining what he said was the underlying cause of her death.

    But Sanofi said it knew of no deaths resulting from the vaccine.


    "In Dengvaxia clinical trials conducted over more than a decade and over one million doses of the vaccine administered, no deaths causally related to the vaccine have been reported to us," it said in a statement.


    Sanofi also rejected a Department of Health (DOH) request to refund the government for used doses of the vaccine, which it said would "imply that the vaccine is ineffective, which is not the case".


    Health Secretary Francisco Duque said the Dengvaxia controversy had "tainted the credibility" of the country's immunization programme.


    Two non-government organizations filed an administrative complaint with the Office of the President on Monday calling for 13 health ministry officials involved in the anti-dengue programme to be dismissed.


    The DOH suspended its dengue immunization programme following a Sanofi advisory late in November that said the vaccine itself may, in some cases, increase the risk of severe dengue in recipients not previously infected by the virus.


    On Friday, a panel of experts tasked by the DOH to determine if the drug was directly connected to the deaths of 14 recipients of the vaccine found it may have been connected to three deaths. It concluded Dengvaxia was not ready for mass immunization.


    Mosquito-borne dengue is the world's fastest-growing infectious disease, afflicting up to 100 million people worldwide, causing half a million life-threatening infections and killing about 20,000 people, mostly children, each year.




    (Additional reporting by Neil Jerome Morales; Editing by Martin Petty)



    Anjielica Pestilosclinical trialscompensationdeathDengue vaccineDengvaxiaDepartment of HealthlawyersPhilippinesSanofisuevaccineZuellig Pharma Corp
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok